Meril at EuroPCR 2026: LANDMARK Trial 2-Year Results and Key Highlights

Paris hosted EuroPCR 2026 from May 19 to 22, with the Palais des Congrès welcoming over 12,000 interventional cardiologists, cardiac surgeons, researchers, and cardiovascular professionals from across the globe.^1,3 Meril Life Sciences was among the participants, with a presence at Level 1, Booths F1 and F4, throughout the four days.

EuroPCR is the annual official congress of the European Association of Percutaneous Cardiovascular Interventions (EAPCI)² and is described by PCR as the world-leading course in interventional cardiovascular medicine.¹ Its programme combines scientific content, clinical trial presentations, live educational cases, educational sessions, hands-on formats, and industry/innovation participation, making it a major forum for scientific exchange and clinical education in the cardiovascular field.³

The primary scientific contribution from Meril at EuroPCR 2026 was the presentation of 2-year outcomes from the LANDMARK Randomised Controlled Trial, which featured in the Late-Breaking Trials session^4,5 — the third consecutive year the trial has appeared in this programme.^5,6,7

About the trial:

• The LANDMARK trial is the first multinational RCT to compare a transcatheter heart valve series from an Indian manufacturer directly against both leading balloon-expandable and self-expandable contemporary platforms.^9,11
• The trial enrolled 768 patients across 31 centers in 16 countries, spanning Europe, Brazil, and New Zealand.⁹

2-year results:

• The composite clinical efficacy endpoint — freedom from all-cause mortality, all stroke, and procedure or valve-related hospitalisation — was comparable between the two groups in the overall cohort (p = 0.39)⁸
• Results were also comparable in the small aortic annuli subset (p = 0.97)⁸
• Results were comparable in the women subset (p = 0.36)⁸

Publication history:

• 30-day data confirmed non-inferiority and was published in The Lancet (Baumbach et al., 2024)⁹
• 12-month follow-up again confirmed non-inferiority — this time in the Journal of the American College of Cardiology (Serruys et al., JACC 2026;87(4):362–381)¹⁰
• At 2 years, clinical efficacy was comparable across the overall patient group, those with small annuli, and women⁸

The trial is designed with a 10-year follow-up, with long-term valve durability and sustained clinical outcomes among the endpoints being tracked.^8,11

Alongside the trial presentation, Meril hosted a series of clinical education sessions under the From Strategy to Success series. Topics included managing TAVI complications in patients with large aortic annuli, procedural planning for re-do TAVI, TAVI in bicuspid anatomy, and CT-based pre-procedural planning using 3mensio imaging software. Sessions were led by an international faculty of interventional cardiologists.

Two live TAVI cases were also transmitted to the conference floor — one from Copenhagen, Denmark and one from Toulouse, France. The cases covered CT planning, commissural alignment, and valve-in-valve procedural strategy.

At the booth, two dedicated spaces shaped most of the activity. The Innovation Suite was where clinicians and experts sat down to work through cases and clinical questions — covering both structural heart and coronary intervention. The Training Village ran alongside it, giving interventional teams direct, hands-on time with the technology. PRISM-PCI, Meril's complex coronary intervention programme, featured across the conference days as well.

The 2-year data is an important milestone, but the LANDMARK trial is far from over. With follow-up continuing to the 10-year mark under the leadership of Professor Patrick Serruys and Professor Andreas Baumbach, questions around long-term valve durability and sustained outcomes in an ageing patient population are still being answered. EuroPCR will likely remain the forum where those answers are shared.

For more information on Meril’s cardiovascular portfolio visit merillife.com/our-products/vascular-intervention.